Helicobacter pylori infection
Conditions
Interventions
Single site sampling group versus Double position sampling group:no
Sponsors
Huzhou Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years old, men and women are not limited; 2. Due to abdominal pain, bloating, acid reflux, belching, nausea, vomiting, heartburn, chest pain, black and so on discomfort symptoms of HP-related diseases; 3. Antibiotics, bismuth, H2 receptor antagonists, or PPI are not used in the last two weeks; 4. Urine breath test was positive; 5. Agreed to endoscopy to take gastric mucosal biopsy specimens were HP culture and drug sensitivity test; 6. Agreed to follow the initial treatment of HP eradication therapy and are willing to follow the doctor's follow-up survey of eradication efficacy.;Inclusion criteria: 1. Aged 18 to 70 years old, men and women are not limited; 2. Due to abdominal pain, bloating, acid reflux, belching, nausea, vomiting, heartburn, chest pain, black and so on discomfort symptoms of HP-related diseases; 3. Antibiotics, bismuth, H2 receptor antagonists, or PPI are not used in the last two weeks; 4. Urine breath test was positive; 5. Agreed to endoscopy to take gastric mucosal biopsy specimens were HP culture and drug sensitivity test; 6. Agreed to follow the initial treatment of HP eradication therapy and are willing to follow the doctor's follow-up survey of eradication efficacy.;Inclusion criteria: 1. Aged 18 to 70 years old, men and women are not limited; 2. Due to abdominal pain, bloating, acid reflux, belching, nausea, vomiting, heartburn, chest pain, black and so on discomfort symptoms of HP-related diseases; 3. Antibiotics, bismuth, H2 receptor antagonists, or PPI are not used in the last two weeks; 4. Urine breath test was positive; 5. Agreed to endoscopy to take gastric mucosal biopsy specimens were HP culture and drug sensitivity test; 6. Agreed to follow the initial treatment of HP eradication therapy and are willing to follow the doctor's follow-up survey of eradication efficacy.;Inclusion criteria: 1. Aged 18 to 70 years old, men and women are not limited; 2. Due to abdominal pain, bloating, acid reflux, belching, nausea, vomiting, heartburn, chest pain, black and so on discomfort symptoms of HP-related diseases; 3. Antibiotics, bismuth, H2 receptor antagonists, or PPI are not used in the last two weeks; 4. Urine breath test was positive; 5. Agreed to endoscopy to take gastric mucosal biopsy specimens were HP culture and drug sensitivity test; 6. Agreed to follow the initial treatment of HP eradication therapy and are willing to follow the doctor's follow-up survey of eradication efficacy.;Inclusion criteria: 1. Aged 18 to 70 years old, men and women are not limited; 2. Due to abdominal pain, bloating, acid reflux, belching, nausea, vomiting, heartburn, chest pain, black and so on discomfort symptoms of HP-related diseases; 3. Antibiotics, bismuth, H2 receptor antagonists, or PPI are not used in the last two weeks; 4. Urine breath test was positive; 5. Agreed to endoscopy to take gastric mucosal biopsy specimens were HP culture and drug sensitivity test; 6. Agreed to follow the initial treatment of HP eradication therapy and are willing to follow the doctor's follow-up survey of eradication efficacy.
Exclusion criteria
Exclusion criteria: 1. Serious heart, liver, kidney damage; 2. Pregnant or lactating women; 3. Patients with other adverse effects such as severe liver disease, heart disease, kidney disease, malignancy and alcoholism, bleeding, perforation, pyloric obstruction, and cancer complications; 4. There are esophagus, gastrointestinal surgery history; 5. Participate in other drug studies within 3 months of the study drug; 6. Patients can not correctly express their complaints, such as mental illness, severe neurosis; 7. Patients with gastric mucosal biopsy contraindications (coagulation disorders, taking anticoagulants, etc.); 8. Patients taking non-steroidal anti-inflammatory drugs or alcohol at the same time; 9. Patients with HP drug susceptibility test antibiotics for any drug allergy.;Exclusion criteria: 1. Serious heart, liver, kidney damage; 2. Pregnant or lactating women; 3. Patients with other adverse effects such as severe liver disease, heart disease, kidney disease, malignancy and alcoholism, bleeding, perforation, pyloric obstruction, and cancer complications; 4. There are esophagus, gastrointestinal surgery history; 5. Participate in other drug studies within 3 months of the study drug; 6. Patients can not correctly express their complaints, such as mental illness, severe neurosis; 7. Patients with gastric mucosal biopsy contraindications (coagulation disorders, taking anticoagulants, etc.); 8. Patients taking non-steroidal anti-inflammatory drugs or alcohol at the same time; 9. Patients with HP drug susceptibility test antibiotics for any drug allergy.;Exclusion criteria: 1. Serious heart, liver, kidney damage; 2. Pregnant or lactating women; 3. Patients with other adverse effects such as severe liver disease, heart disease, kidney disease, malignancy and alcoholism, bleeding, perforation, pyloric obstruction, and cancer complications; 4. There are esophagus, gastrointestinal surgery history; 5. Participate in other drug studies within 3 months of the study drug; 6. Patients can not correctly express their complaints, such as mental illness, severe neurosis; 7. Patients with gastric mucosal biopsy contraindications (coagulation disorders, taking anticoagulants, etc.); 8. Patients taking non-steroidal anti-inflammatory drugs or alcohol at the same time; 9. Patients with HP drug susceptibility test antibiotics for any drug allergy.;Exclusion criteria: 1. Serious heart, liver, kidney damage; 2. Pregnant or lactating women; 3. Patients with other adverse effects such as severe liver disease, heart disease, kidney disease, malignancy and alcoholism, bleeding, perforation, pyloric obstruction, and cancer complications; 4. There are esophagus, gastrointestinal surgery history; 5. Participate in other drug studies within 3 months of the study drug; 6. Patients can not correctly express their complaints, such as mental illness, severe neurosis; 7. Patients with gastric mucosal biopsy contraindications (coagulation disorders, taking anticoagulants, etc.); 8. Patients taking non-steroidal anti-inflammatory drugs or alcohol at the same time; 9. Patients with HP drug susceptibility test antibiotics for any drug allergy.;Exclusion criteria: 1. Serious heart, liver, kidney damage; 2. Pregnant or lactating women; 3. Patients with other adverse effects such as severe liver disease, heart disease, kidney disease, malignancy and alcoholism, bleeding, perforation, pyloric obstruction, and cancer complications; 4. There are esophagus, gastrointestinal surgery history; 5. Participate in other drug studies within 3 months of the study drug; 6. Patients can not correctly express their complaints, such as mental illness, severe neurosis; 7. Patients with gastric mucosal biopsy contraindications (coagulation disorders, taking anticoagulants, etc.); 8. Patients taking non-steroidal anti-inflammatory drugs or alcohol at the same time; 9. Patients with HP drug susceptibility test antibiotics for any drug allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HP eradication rate; | — |
Countries
China
Contacts
Public ContactJieming Shi;Jieming Shi;Jieming Shi;Jieming Shi;Jieming Shi ;;;;
Huzhou Central Hospital;Huzhou Central Hospital;Huzhou Central Hospital;Huzhou Central Hospital;Huzhou Central Hospital
Outcome results
None listed